Johnson & Johnson (J&J) is an American multinational corporation which was founded in 1886. It develops medical devices, pharmaceuticals, and consumer packaged goods.
Its common stock is a component of the Dow Jones Industrial Average. The company is ranked No. 37 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.
Also Read: Omicron Symptoms Timeline Day by Day | Latest Strain of Covid Symptoms
Johnson And Johnson Company
Johnson & Johnson is one of the world’s most valuable companies. It is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Johnson & Johnson has it’s headquartered in New Brunswick, New Jersey. The consumer division is located in Skillman, New Jersey. The corporation includes approximately 250 subsidiary companies with operations in 60 countries.
Also Read: What is the Nipah Virus | Nipah Virus Outbreak & Symptoms
The Johnson and Johnson products are sold in over 175 countries. Johnson & Johnson’s brands include numerous household names of medications and first aid supplies.
Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson’s baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson’s pharmaceutical arm is Janssen Pharmaceutical.
Read More: Moderna Vaccine Efficiency | Moderna Covid Vaccine Side effects | Moderna Covid Vaccine Authorization
Facts About Johnson And Johnson Covid19 Vaccine
The Company has committed over $1 billion for the development of the Johnson And Johnson COVID-19 vaccine in partnership with the Biomedical Advanced Research and Development Authority (BARDA) Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S.
Department of Health and Human Services (HHS). They will produce the Johnson And Johnson COVID-19 Vaccine in the not-for-profit category.
Janssen Vaccines partnered with Beth Israel Deaconess Medical Center, to develop a vaccine candidate based on the same technology used to make its Ebola vaccine. The vaccine uses a replication-incompetent human adenovirus.
Read More: Effectiveness of Covishield vaccine in preventing Covid-19 | Covishield Vaccine Side Effect & Efficacy
Effectiveness of Johnson And Johnson Covid-19 Vaccine
In July 2020, the vaccine candidate entered a Phase 1 human clinical study. In September 2020, Johnson & Johnson started its 60,000-person Phase III adenovirus-based vaccine trial.
The trial was temporarily halted in October 2020, as a trial participant became ill. The company resumed the trial in late October 2020 after it was announced that no evidence was found that the vaccine caused the illness.
Also Read: Covid-19 Vaccine Registration Online | How to get Covid 19 Vaccine Certificate Online
In January 2021, Johnson & Johnson released an efficacy report based on data from the Phase III trial of its single-shot vaccine.
As per the data gathered in the trial, the vaccine was 66% effective in preventing moderate-to-severe forms of COVID-19 in people who received the shot.
It was 85% effective in preventing severe cases. On February 27, the FDA approved it for emergency use in the United States in individuals 18 and older.
Approvals of Johnson And Johnson Covid-19 Vaccine
Beginning on 1 December 2020, the clinical trial of the vaccine candidate has been undergoing a “rolling review” process by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA).
This is a step to expedite EMA’s consideration of an expected conditional Marketing Authorisation Application. On 16 February 2021, Janssen applied to the EMA for conditional marketing authorization of the vaccine.
The European Commission approved the COVID-19 Vaccine Janssen on 11 March 2021. On 4 February 2021, Janssen Biotech applied to the U.S. Food and Drug Administration (FDA) for an EUA.
Johnson & Johnson announced that it planned to ship the vaccine immediately after authorization.
On 24 February 2021, the FDA document recommended granting the EUA with a conclusion that the results of the clinical trials and safety data are consistent with FDA EUA guidance for COVID-19 vaccines.
At the 26 February meeting, VRBPAC voted unanimously (22–0) to recommend that an EUA for the vaccine be issued.
The FDA granted the EUA for the vaccine the following day. On 28 February, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommended the use of the vaccine for those aged 18 and older.
Also Read: What happens if you mix COVID-19 vaccines? | Is the COVID-19 vaccine no longer authorized
The CDC and the FDA issued a joint statement recommending that the use of the Johnson & Johnson vaccine be suspended, due to reports of six cases of cerebral venous sinus thrombosis—a “rare and severe” blood clot—in combination with low levels of blood platelets (thrombocytopenia), in six women between the ages of 18 and 48 who had received the vaccine On 13 April 2021.
The FDA and the CDC determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume On 23 April.
The EUA and the fact sheets were updated to reflect the risks of thrombosis-thrombocytopenia syndrome (TTS).
Also Read: Effectiveness of COVID 19 vaccine (Covaxin) against SARS-CoV-2 Infection
Availability of Johnson And Johnson COVID-19 Vaccine
In April 2020, Johnson & Johnson formed a partnership with Catalent to provide large-scale manufacturing of the Johnson And Johnson COVID-19 vaccine at Catalent’s Bloomington and Italian facility.
In July 2020, Johnson & Johnson decided to produce up to 300 million doses of its COVID-19 vaccine for the U.S.
The deal is worth approximately more than $1 billion and was funded by the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Defence Department.
In September 2020, Grand River Aseptic Manufacturing accepted to support the manufacture of its SARS-CoV-2 vaccine candidate, including technology transfer and fill and finish manufacture.
In December 2020, Johnson & Johnson and Reig Jofre, a Spanish pharmaceutical company, signed an agreement to manufacture the vaccine at Reig Jofre’s Barcelona facility.
If the European Medicines Agency (EMA) grants approval to the vaccine by March 2021, a European Union regulator said Johnson & Johnson could start supplying vaccines to EU states starting in April 2021.
In August 2020, Johnson & Johnson signed a contract with the U.S. federal government for $1 billion, agreeing to deliver one hundred million doses of its.
In April 2020, Johnson & Johnson formed a partnership with Catalent to provide large-scale manufacturing of the Johnson And Johnson COVID-19 Vaccine at Catalent’s Bloomington and Italian facility to the U.S. following the U.S. Food and Drug Administration (FDA) grant of approval or Emergency Use Authorization (EUA) for the vaccine.
Under its agreement with the U.S. government, Johnson & Johnson had targeted to produce twelve million doses by the end of February 2021, more than sixty million doses by the end of April 2021, and more than one hundred million doses by the end of June 2021.
However, in January 2021, Johnson & Johnson acknowledged manufacturing delays would likely prevent it from meeting its contract of twelve million doses delivered to the U.S. by the end of February.
In February 2021, congressional testimony by a company executive, however, Johnson & Johnson indicated that the company could deliver twenty million doses to the U.S. government by the end of March, and one hundred million doses in the first half of 2021.
Sanofi and Johnson & Johnson struck a deal for Sanofi to provide support and infrastructure at Sanofi’s Marcy-l’Étoile, France facility to manufacture approximately twelve million doses of the Johnson & Johnson vaccine per month once authorized In February 2021.
Also Read: This 30 Minute Yoga Asanas Will Change Your Life | 30-Minute Yoga Sequence
In March 2021, Johnson & Johnson and Aspen Pharmacare made a deal to manufacture 220 million vaccines at Aspen’s Gqeberha facility in Eastern Cape, South Africa.
They plan to distribute the vaccine to other countries, mainly in Africa and through the COVID-19 Vaccines Global Access (COVAX) program.
In March 2021, Merck & Co and Johnson & Johnson struck a deal for Merck to manufacture the Johnson & Johnson vaccine at two facilities in the United States to help expand the manufacturing capacity of the vaccine using provisions of the Defense Production Act.
That same month, human error at a plant run by Emergent BioSolutions in Baltimore resulted in the spoilage of up to fifteen million doses of the Johnson & Johnson vaccine.
The error, which was caught before the doses left the plant, delayed expected shipments of the Johnson & Johnson vaccine within the United States.
As the error had involved combining ingredients of the Johnson & Johnson vaccine with the AstraZeneca vaccine, the Biden administration gave control of the plant to Johnson & Johnson and said the plant should produce only the Johnson & Johnson vaccine to avoid further mix-ups.
Also Read: Benefits of Ashwagandha for Men and Women | Proven Health Benefits of Ashwagandha and Side Effects
Johnson And Johnson Covid-19 Vaccine Card
Click Here to Know More – Proof of vaccination: requirements and validity
Johnson And Johnson Covid-19 Vaccine: FAQ
How Effective Is the Johnson And Johnson Vaccine
As per the data gathered in the trial, the vaccine was 66% effective in preventing moderate-to-severe forms of COVID-19 in people who received the shot. It was 85% effective in preventing severe cases. On February 27, the FDA approved it for emergency use in the United States in individuals 18 and older.
Does the Johnson And Johnson Vaccine use Fetal Stem Cells?
No, Johnson & Johnson does not contain any fetal cell lines in the vaccine. While vaccines use lab-replicated fetal cells during their production process.
Where I can get Johnson And Johnson Vaccine Near Me
To find the Vaccine Site Click Here. You can find the vaccine Spot at https://www.vaccines.gov/search/.
Is Johnson And Johnson Vaccine MRNA
mRNA is an essential little piece of code that the Vaccine delivers to your cells. Johnson& Johnson Vaccine uses more traditional virus-based technology. The Moderna and Pfizer vaccines use mRNA technology.
Is Johnson And Johnson Vaccine Safe
On 24 February 2021, the FDA document recommended granting the EUA with a conclusion that the results of the clinical trials and safety data are consistent with FDA EUA guidance for COVID-19 vaccines. At the 26 February 2021 meeting, VRBPAC voted unanimously (22–0) to recommend that an EUA for the vaccine be issued.
Read More:
- Who is Byju Raveendran and His Wife Divya Gokulnath | Interesting Facts About Byju Raveendran and His Net Worth
- The Kashmir Files Movie Review (2022) a True Story of Kashmiri Pandits
- Top 10 Best Animation & VFX College in India Online & Offline
- Top 10 Canadian Cuisines You Must Try in Your Life
- Amazing facts about Google | Wierd facts about Google | Tell me more about Google
About Author
